Core Viewpoint - Betta Pharmaceuticals has announced that several of its products have been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance the accessibility and market potential of these drugs [1] Group 1 - Betta Pharmaceuticals' products included in the 2025 drug list are: - Hydrochloride Alectinib Tablets (Kaimena) - Hydrochloride Ensartinib Capsules (Beimana) - Mesylate Bafetinib Capsules (Saimena) - Voronib Tablets (Fumeina) [1] - Additionally, the company's Bevacizumab Injection (Beanding) has been included in the National Medical Insurance Category B drug list [1]